8-K: AirSculpt Technologies Reports Q3 2024 Results, Affirms Full-Year Guidance

AirSculpt Technologies announced its third-quarter results for 2024, reporting a revenue of $42.5 million and affirming its full-year guidance.

Summary

• AirSculpt Technologies reported a revenue of $42.5 million for the third quarter of 2024, a 9.1% decrease compared to $46.8 million in the same period of 2023.
• The company experienced a net loss of $6.0 million in Q3 2024, compared to a net loss of $1.7 million in Q3 2023.
• Adjusted EBITDA for the third quarter was $4.7 million, down from $9.1 million in the prior year's third quarter.
• Case volume for Q3 2024 was 3,277, a 4.3% decrease from 3,426 in Q3 2023.
• For the first nine months of 2024, revenue was $141.2 million, a 4.8% decrease from $148.3 million in the same period of 2023.
• The net loss for the first nine months of 2024 was $3.2 million, compared to a net income of $0.1 million in the same period of 2023.
• Adjusted EBITDA for the first nine months of 2024 was $18.9 million, down from $33.1 million in the prior year period.
• The company reaffirmed its full-year 2024 revenue guidance of $183 million to $189 million and adjusted EBITDA guidance of $23 million to $28 million.
• AirSculpt opened four new centers during the third quarter and plans to open five new centers in 2024.
• As of September 30, 2024, the company had $6.0 million in cash and cash equivalents and $5.0 million of borrowing capacity.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to decreased revenue, increased net loss, and reduced EBITDA, although the company is maintaining its full-year guidance and opening new centers. The challenges in same-center sales and the consumer environment are concerning.

Positives

• The company opened four new centers during the third quarter, contributing to growth.
• The 2023 de novo class of centers continues to surpass expectations.
• The company reaffirmed its full-year revenue and adjusted EBITDA guidance.
• AirSculpt is focused on improving lead conversion and cost reduction efforts.
• The company has $5.0 million of borrowing capacity under its revolving credit facility.

Negatives

• Third-quarter revenue decreased by 9.1% year-over-year.
• The company experienced a net loss of $6.0 million in the third quarter, compared to a loss of $1.7 million in the same period last year.
• Adjusted EBITDA decreased to $4.7 million in the third quarter, down from $9.1 million in the prior year.
• Case volume declined by 4.3% in the third quarter.
• Same-center sales remain down, indicating challenges in existing locations.
• Operating cash flow decreased to $8.6 million for the first nine months of 2024, compared to $19.1 million in the same period of 2023.

Risks

• The company faces challenges in the current consumer environment.
• There is a risk of not being able to improve the conversion of leads to consults and cases.
• The company is exposed to increased competition in the weight loss and obesity solutions market.
• Rising interest rates and inflation could impact the ability to open new centers.
• The company is subject to risks related to litigation and medical malpractice claims.
• There are risks associated with changes in laws governing the corporate practice of medicine or fee-splitting.
• The company is exposed to macroeconomic conditions, including inflation and the threat of recession.

Future Outlook

The company reaffirmed its full-year 2024 revenue guidance of $183 million to $189 million and adjusted EBITDA guidance of $23 million to $28 million. They also plan to open five new centers in 2024.

Management Comments

• Our revenue and Adjusted EBITDA for the quarter were in line with our expectations with the period including progress on our strategy despite continued challenges in the consumer environment said Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer of AirSculpt Technologies, Inc.
• We are pleased with our four new center openings during the quarter and our 2023 de novo class continues to surpass our expectations.
• While our same center sales remain down, we are focused on improving the conversion of leads to consults and cases and believe this, combined with our new center openings and our cost reduction efforts, has us on the right track to return to positive revenue growth while also improving our margins over time.

Industry Context

The results reflect a challenging consumer environment and increased competition in the weight loss and obesity solutions market, which is impacting the company's performance. The company is focusing on improving lead conversion and cost reduction to address these challenges.

Comparison to Industry Standards

• AirSculpt's revenue decline of 9.1% in Q3 2024 contrasts with some competitors in the aesthetic medicine space who have shown more resilience or growth, such as InMode which reported a 20% increase in revenue in their most recent quarter.
• The decrease in AirSculpt's adjusted EBITDA margin to 11.0% in Q3 2024, compared to 19.4% in the same period last year, is a significant drop and is below the industry average for medical aesthetic companies, which typically aim for margins above 20%.
• While AirSculpt is expanding its footprint with new centers, the decline in same-center sales indicates a need to improve operational efficiency and marketing strategies, similar to challenges faced by other multi-location healthcare providers like LaserAway.
• The company's focus on cost reduction and lead conversion is a common strategy in the industry, but the effectiveness of these measures will determine its ability to compete with companies like Cynosure, which have a broader range of products and services.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue, increased net loss, and reduced EBITDA.
• Employees may be affected by cost reduction efforts.
• Customers may benefit from the opening of new centers.
• Suppliers may be impacted by changes in the company's financial performance.
• Creditors may be concerned about the company's decreased operating cash flow.

Next Steps

• The company will focus on improving the conversion of leads to consults and cases.
• AirSculpt will continue its cost reduction efforts.
• The company plans to open five new centers in 2024.
• AirSculpt will hold a conference call to discuss the results.

Key Dates

Keywords

AirSculpt, body contouring, revenue, EBITDA, net loss, case volume, financial results, guidance, healthcare, medical procedures